Journal Article

Psychotropic Drugs in Patients with Cushing’s Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study

Edén Engström, Britt, Berinder, Katarina, Dahlqvist, Per, Burman, Pia, Bengtsson, Daniel, Höybye, Charlotte, Ragnarsson, Oskar, Wahlberg, Jeanette, Ekman, Bertil

2021

Overview

Abstract Context Psychiatric symptoms are common in Cushing’s disease (CD) and seem only partly reversible following treatment. Objective To investigate drug dispenses associated to psychiatric morbidity in CD patients before treatment and during long-term follow-up. Design Nationwide longitudinal register-based study. Setting University Hospitals in Sweden. Subjects CD patients diagnosed between 1990 and 2018 (N = 372) were identified in the Swedish Pituitary Register. Longitudinal data was collected from 5 years before, at diagnosis, and during follow-up. Four matched controls per patient were included. Cross-sectional subgroup analysis of 76 patients in sustained remission was also performed. Main outcome measures Data from the Swedish Prescribed Drug Register and the Patient Register. Results In the 5-year period before and at diagnosis, use of antidepressants (odds ratio [OR] 2.2 [95% confidence interval (CI) 1.3-3.7]) and 2.3 [1.6-3.5]), anxiolytics [2.9 (1.6-5.3) and 3.9 (2.3-6.6)], and sleeping pills [2.1 (1.2-3.7) and 3.8 (2.4-5.9)] was more common in CD than controls. ORs remained elevated at 5-year follow-up for antidepressants [2.4 (1.5-3.9)] and sleeping pills [3.1 (1.9-5.3)]. Proportions of CD patients using antidepressants (26%) and sleeping pills (22%) were unchanged at diagnosis and 5-year follow-up, whereas drugs for hypertension and diabetes decreased. Patients in sustained remission for median 9.3 years (interquartile range 8.1-10.4) had higher use of antidepressants [OR 2.0 (1.1-3.8)] and sleeping pills [2.4 (1.3-4.7)], but not of drugs for hypertension. Conclusions Increased use of psychotropic drugs in CD was observed before diagnosis and remained elevated regardless of remission status, suggesting persisting negative effects on mental health. The study highlights the importance of early diagnosis of CD, and the need for long-term monitoring of mental health.

• Publisher: Oxford University Press
• Subject: Adrenocorticotropic hormone / Adult / Antidepressants / Antidepressants, Tricyclic / Anxiolytics / Care and treatment / Clinical Medicine / Clinical s / Cross-Sectional Studies / Cushing's syndrome / depression / Depression, Mental / Diabetes mellitus / Diagnosis / Drugs / Endocrinology & Metabolism / Endocrinology and Diabetes / Endokrinologi och diabetes / Female / Follow-Up Studies / Health aspects / Humans / hypercortisolism / Hypertension / Hypnotics / Klinisk medicin / Longitudinal Studies / Male / manifestations / Medical and Health Sciences / Medicin och hälsovetenskap / Mental Disorders - drug therapy / Mental Disorders - epidemiology / Mental Disorders - etiology / Mental health / Middle Aged / Morbidity / Nervous system diseases / neuropsychiatric disorders / neuropsychiatry / Patients / Pharmacy / Pituitary / Pituitary ACTH Hypersecretion - complications / Pituitary ACTH Hypersecretion - diagnosis / Pituitary ACTH Hypersecretion - drug therapy / Pituitary ACTH Hypersecretion - epidemiology / Prescribing / prevalence / psychopathology / Psychotropic drugs / Psychotropic Drugs - therapeutic use / reductions / Remission / Remission (Medicine) / Retrospective Studies / Sleep disorders / sleeping disorder / Sweden - epidemiology / symptoms